Form 8-K
8-K — Cadrenal Therapeutics, Inc.
Accession: 0001213900-26-069902
Filed: 2026-06-18
Period: 2026-06-18
CIK: 0001937993
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Regulation FD Disclosure
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — ea0295234-8k_cadrenal.htm (Primary)
EX-99.1 — PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON JUNE 18, 2026 (ea029523401ex99-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0295234-8k_cadrenal.htm · Sequence: 1
false
0001937993
0001937993
2026-06-18
2026-06-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
June 18, 2026
Cadrenal Therapeutics, Inc.
(Exact name of registrant as specified in charter)
Delaware
001-41596
88-0860746
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
(Address of principal executive offices and zip
code)
(904) 300-0701
(Registrant’s telephone number including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General
Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbols
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CVKD
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by checkmark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On June 18, 2026, Cadrenal Therapeutics, Inc.
(the “Company”) issued a press release announcing its plans to submit a Rare Pediatric Disease Designation (“RPDD”)
request to the U.S. Food and Drug Administration (“FDA”) for tecarfarin as a treatment for pediatric patients with Kawasaki
disease who develop coronary artery aneurysms (“CAAs”) and require chronic oral anticoagulation.
The Company also disclosed its dual-track portfolio
strategy that includes: (i) The Global Pharma Track: Focusing on CAD-1005, a first-in-class 12-LOX inhibitor; and (ii) The Regional &
Rare Disease Track: Focusing on tecarfarin for Kawasaki disease.
A copy of the press release is furnished herewith
as Exhibit 99.1. The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K
shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated
by reference into any filing with the Securities and Exchange Commission (the “SEC”) made by the Company, whether made before
or after the date hereof, regardless of any general incorporation language in such filing.
Item 8.01. Other Events.
On June 18, 2026, the Company issued a press release
announcing its plans to submit a RPDD request to the FDA for tecarfarin as a treatment for pediatric patients with Kawasaki disease who
develop coronary artery aneurysms and require chronic oral anticoagulation.
The Company also disclosed its dual-track portfolio
strategy that includes: (i) The Global Pharma Track: Focusing on CAD-1005, a first-in-class 12-LOX inhibitor; and (ii) The Regional &
Rare Disease Track: Focusing on tecarfarin for Kawasaki disease.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are furnished with
this Current Report on Form 8-K:
Exhibit
Number
Exhibit Description
99.1
Press Release, issued by Cadrenal Therapeutics, Inc. on June 18, 2026
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)
1
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 18, 2026
CADRENAL THERAPEUTICS, INC.
By:
/s/ Quang X. Pham
Name:
Quang X. Pham
Title:
Chairman and Chief Executive Officer
2
EX-99.1 — PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON JUNE 18, 2026
EX-99.1
Filename: ea029523401ex99-1.htm · Sequence: 2
Exhibit 99.1
Cadrenal Therapeutics to File for FDA Rare
Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Company to present Phase 3-ready pipeline,
12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San
Diego
Kawasaki disease is the leading cause of acquired
heart disease in children in developed nations. Patients are at risk of forming blood clots in coronary arteries and may require lifelong
treatment
If the designation is granted and tecarfarin
is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher—recent open-market valuations
for these vouchers have reached into the ~$200 million range
PONTE VEDRA, FL — June 18, 2026 — Cadrenal Therapeutics,
Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions,
today announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for
tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require
chronic oral anticoagulation.
The announcement comes ahead of the BIO International Convention,
June 22–25, 2026, in San Diego, California. Cadrenal’s executive leadership team will highlight this rare pediatric initiative
and its Phase 3-ready CAD-1005 platform during one-on-one partnering meetings with global and regional pharmaceutical companies.
KD is an acute inflammatory illness and the leading cause of acquired
heart disease in children in developed nations. Up to 25% of untreated children with KD develop enlarged coronary arteries or CAAs. Patients
with large CAAs are at risk for forming blood clots in those blood vessels – with a continuing lifelong risk for subsequent heart
attacks and sudden cardiac death - and require chronic, precise anticoagulation therapy to reduce their higher risk of clot formation.
Tecarfarin is a novel, next-generation Vitamin K antagonist (VKA)
that offers a number of potential advantages over warfarin, the current standard VKA in clinical use. Specifically, tecarfarin is designed
to overcome limitations of warfarin metabolism and potentially provide more reliable and more consistent anticoagulation than might be
possible with warfarin.
“Children with large or giant aneurysms due to KD represent an
important underserved orphan population,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “The current
standard of care – warfarin - is notoriously unstable in children because of dietary variations, concurrent medications, and genetic
differences in liver metabolism. Tecarfarin is metabolized in a completely different way than warfarin, and is being developed to offer
a highly stable, predictable alternative. We believe tecarfarin can potentially improve time in therapeutic range for these children,
thereby lowering their risk for both catastrophic blood clots and dangerous bleeding events.”
The FDA’s RPDD program targets serious or life-threatening diseases
that primarily affect fewer than 200,000 people in the United States from birth through age 18. If the FDA grants the designation and
tecarfarin is subsequently approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher (PRV). These
transferable vouchers can be used to accelerate the FDA review of a future drug or sold to another pharmaceutical manufacturer. Following
Congress’s extension of the pediatric PRV program through September 30, 2029, recent open-market valuations for these vouchers have reached
record highs, with recent sales ranging from $180 million to $205 million.
At the upcoming BIO International Convention, Cadrenal will
present a dual-track portfolio strategy designed to maximize value for potential partners:
● The
Global Pharma Track: Focusing on CAD-1005, a first-in-class 12-LOX inhibitor. CAD-1005
is Phase 3-ready for Heparin-Induced Thrombocytopenia (HIT) and is advancing into a Phase
2a trial for Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), addressing a combined,
multi-billion-dollar dual-indication acute hospital care market.
● The
Regional & Rare Disease Track: Focusing on tecarfarin for Kawasaki disease. This
program offers an efficient clinical trial design and strong geographic synergy, particularly
for Japanese and East Asian pharmaceutical companies, where the incidence of Kawasaki disease
is historically 10 to 15 times higher than in Western nations.
“Our presence at BIO 2026 centers on executing capital-efficient
development strategies,” added Mr. Pham. “If we are successful in advancing tecarfarin toward a RPDD, we will create a high-value,
de-risked regulatory pathway that aligns with regional partners’ portfolio needs while directing our core internal resources toward our
blockbuster CAD-1005 critical care franchise.”
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic
conditions. The company’s pipeline includes CAD-1005, a novel first-in-class 12-LOX inhibitor targeting multiple critical care
indications, and tecarfarin, a late-stage oral anticoagulant designed to avoid CYP450 metabolism. CAD-1005 has received Orphan Drug
and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines
Agency, for the treatment of Heparin-Induced Thrombocytopenia (HIT). CAD-1005 is also being developed for use in Cardiac Surgery-Associated
Acute Kidney Injury (CSA-AKI), and second-generation 12-LOX oral therapeutics are in development for chronic indications.
2
About Tecarfarin
The Company’s broader pipeline includes tecarfarin, a late-stage
oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation,
including those with end-stage kidney disease and those with left ventricular assist devices. Tecarfarin has also received Orphan Drug
and Fast Track designations from the U.S. Food and Drug Administration.
Safe Harbor Statement
Any statements in this press release about future expectations, plans,
and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking
statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potentially,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements
include, without limitation, statements regarding plans to file for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki
Disease; Cadrenal being eligible to receive a Priority Review Voucher and the value of the voucher; tecarfarin offering a number
of potential advantages over warfarin, tecarfarin overcoming limitations of warfarin metabolism and potentially providing more reliable
and more consistent anticoagulation than might be possible with warfarin; tecarfarin offering a highly stable, predictable alternative
to warfarin; tecarfarin potentially improving time in therapeutic range for these children, thereby lowering their risk for both catastrophic
blood clots and dangerous bleeding events and the successful advancement of tecarfarin creating a high-value, de-risked regulatory pathway
that aligns with regional partners’ portfolio needs while directing the Company’s core internal resources toward its CAD-1005 critical
care franchise Actual results may differ materially from those indicated by such forward-looking statements as a result of various important
factors, including the ability to raise sufficient capital to continue progress of CAD-1005; the ability for tecarfarin to receive a
Rare Pediatric Disease Designation for treatment of Kawasaki Disease; the ability to monetize a priority review voucher if received,
the ability to successfully design and complete a dual-track portfolio strategy and maximize value for potential partners; the ability
of tecarfarin to overcome limitations of warfarin metabolism and potentially provide more reliable and more consistent anticoagulation
than might be possible with warfarin; the ability of tecarfarin offering a highly stable, predictable alternative to warfarin; tecarfarin
potentially improving time in therapeutic range for children with Kawasaki Disease, thereby lowering their risk for both catastrophic
blood clots and dangerous bleeding events and the successful advancement of tecarfarin creating a high-value, de-risked regulatory pathway
that aligns with regional partners’ portfolio needs; ; the ability to successfully design and complete the Phase 3 study and derive the
results needed for an NDA submission: and the other risk factors described in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2025, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent
periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this
press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims
any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, visit https://www.cadrenal.com/ and
connect with the Company on LinkedIn.
For more information, please contact:
Lytham Partners, LLC, Robert Blum, Managing Partner, 602-889-9700,
CVKD@lythampartners.com
3
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Cover
Jun. 18, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Jun. 18, 2026
Entity File Number
001-41596
Entity Registrant Name
Cadrenal Therapeutics, Inc.
Entity Central Index Key
0001937993
Entity Tax Identification Number
88-0860746
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
822 A1A North
Entity Address, Address Line Two
Suite 306
Entity Address, City or Town
Ponte Vedra
Entity Address, State or Province
FL
Entity Address, Postal Zip Code
32082
City Area Code
904
Local Phone Number
300-0701
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.001 per share
Trading Symbol
CVKD
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
true
Elected Not To Use the Extended Transition Period
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration